Vincristine, doxorabicin, cyclophosphamide, prednisone and etoposide (VACPE) in high-grade non-Hodgkin's lymphoma — a multicenter phase II study

Armitage, 1992, Chemotherapy for non-Hodgkin’s lymphoma, Curr Opin Oncol, 4, 840, 10.1097/00001622-199210000-00005 Salles, 1994, Chemotherapy of non-Hodgkin’s aggressive lymphomas, Semin Hematol, 31, 46 Shipp, 1990, The m-BACOD combination chemotherapy regimen in large-cell lymphoma: Analysis of the completed trial and comparison with the M-BACOD regimen, J Clin Oncol, 8, 84, 10.1200/JCO.1990.8.1.84 Coiffier, 1989, LNH-84 regimen: A multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma, J Clin Oncol, 7, 1018, 10.1200/JCO.1989.7.8.1018 Caracciolo, 1993, Third generation chemotherapy with P-VABEC for aggressive non-Hodgkin’s lymphomas of the elderly, Leuk Lymphoma, 1, 115, 10.3109/10428199309054738 Takagi, 1993, A comparative study of CHOP versus MEVP (mitoxantrone, etoposide, vindesine, prednisolone) therapy for intermediate-grade and high-grade non-Hodgkin’s lymphoma: A prospective randomized study, In J Hematol, 57, 67 Somers R, Carde P, Thomas J et al. and EORTC study of non-Hodgkin’s lymphoma. Phase III study comparing CHVmP-VB and ProMACE-MOPP in patients with stage II, III, and IV intermediate- and high-grade lymphoma. Ann Oncol 5 (Suppl 2): 85–9. Sertoli, 1994, MACOP-B versus Pro-MACE-MOPP in the treatment of advanced diffuse non-Hodgkin’s lymphoma: Results of a prospective randomized trial by the non-Hodgkin’s Lymphoma Cooperative Study Group, J Clin Oncol, 12, 1366, 10.1200/JCO.1994.12.7.1366 Cooper, 1994, (New Zealand Lymphoma Group), Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin’s lymphoma. J Clin Oncol, 12, 769 Fisher, 1993, Comparison of CHOP vs, m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate or high-grade non-Hodgkin’s lymphomas. N Engl J Med, 328, 1002 Gianni, 1990, Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin’s lymphoma, J Clin Oncol, 8, 768, 10.1200/JCO.1990.8.5.768 Gerhartz, 1993, Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin’s lymphomas, Blood, 82, 2329, 10.1182/blood.V82.8.2329.2329 Bergmann, 1995, Recombinant human granulocyte-macrophage colony-stimulating factor after combined chemotherapy in high-grade non-Hodgkin lymphomas – a randomized pilot study Vose, 1993, Role of autologous bone marrow transplantation in non-Hodgkin’s lymphoma, Hematol Oncol Clin North Am, 7, 577, 10.1016/S0889-8588(18)30232-6 Hagenbeek, 1994, Autologous bone marrow transplantation versus CHOP chemotherapy in slowly responding patients with intermediate- and high-grade malignant non-Hodgkin’s lymphoma, Results from a prospective randomized phase III clinical trial in 316 patients. Br J Haematol, 87, 220 Haioun, 1994, and the Group d’Étude des Lymphomes de l’Adulte, Comparison of autologous bone marrow transplantation with sequential chemotherapy for lymphoma in first complete remission: A study of 464 patients. J Clin Oncol, 12, 2543 Young, 1992, Etoposide in the treatment of non-Hodgkin’s lymphomas, Semin Oncol, 11, 1 Martelli, 1993, P-VABEC: A prospective study of a new weekly chemotherapy regimen for elderly aggressive non-Hodgkin’s lymphoma, J Clin Oncol, 11, 2362, 10.1200/JCO.1993.11.12.2362 Lennert, 1990 Carbone, 1971, Report of the committee on Hodgkin’s disease staging, Cancer Res, 31, 1860 Kaplan, 1958, Nonparametric estimation from incomplete observations, J Am Stat Assoc, 53, 457, 10.1080/01621459.1958.10501452 1993, A predictive model for aggressive non-Hodgkin’s lymphoma, The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med, 329, 987 Mantel, 1966, Evaluation of survival data and two new rank order statistics arising in its consideration, Cancer Chemother Rep, 50, 163 Shipp, 1994, Prognostic factors in aggressive non-Hodgkin’s lymphoma: who has ‘high-risk’ disease, Blood, 3, 1165, 10.1182/blood.V83.5.1165.1165 Zuckerman, 1994, Efficacy of intensive, high-dose anthracycline-based therapy in intermediate- and high-grade non-Hodgkin’s lymphomas, Semin Oncol, 21, 59 Lepage, 1993, Prognostic significance of received relative dose intensity in non-Hodgkin’s lymphoma patients: Application to LNH-87 protocol, The GELA. (Groupe d’Étude des Lymphomes de l’Adulte). Ann Oncol, 4, 651 Bronchud, 1993, The importance of dose: Lymphomas as a model of chemosensitive malignancies, Eur J Cancer, 29A, S17, 10.1016/0959-8049(93)90620-U Lishner, 1994, The response of diffuse large cell and other intermediate grade non-Hodgkin’s lymphomas to adriamycin containing combination chemotherapy, Leuk Lymphoma, 13, 131, 10.3109/10428199409051663 Urba, 1992, Recent National Cancer Institute lymphoma trials of etoposide-containing combination chemotherapy, Semin Oncol, 11, 26 Thompson, 1993, Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms: A phase I/II study, J Clin Oncol, 11, 1322, 10.1200/JCO.1993.11.7.1322 Greco, 1993, Chronic etoposide administration: Overview of clinical experience, Cancer Treat Rev, 11, 35, 10.1016/0305-7372(93)90046-T Ang, 1993, MACOP-B in advanced non-Hodgkin’s lymphoma, Am J Clin Oncol, 16, 315, 10.1097/00000421-199308000-00007 Goss, 1993, Non-Hodgkin’s lymphomas in elderly patients, Leuk Lymphoma, 10, 147, 10.3109/10428199309145876